We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01470716
Recruitment Status : Active, not recruiting
First Posted : November 11, 2011
Last Update Posted : April 6, 2022
Sponsor:
Collaborator:
Hoffmann-La Roche
Information provided by (Responsible Party):
Ji-youn Han, National Cancer Center, Korea

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : December 31, 2021
Estimated Study Completion Date : June 30, 2022